China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a Phase II clinical study for its proprietary first-in-class proteolysis targeting chimera (PROTAC) compound, GT20029. The molecule is under development as a treatment for male androgenetic alopecia (AGA), and this marks the first time a topical PROTAC compound has reached the Phase II clinical stage globally.
Phase II Trial Design and Leadership
The trial, conducted across 12 centers, is led by Professor Yang Qinping from Fudan University Huashan Hospital, who serves as the principal investigator. The study’s primary endpoint is the change from baseline in non-vellus target area hair counts (TAHC) after 12 weeks of treatment, with comparisons made against a placebo group.
Previous Phase I Success and Safety Profile
Kintor Pharma has previously completed Phase I clinical trials for GT20029 in both China and the US. Top-line data from over 200 subjects have shown that GT20029 exhibits a good safety profile and is well-tolerated for both single and multiple doses of topical application.-Fineline Info & Tech
